Cancer Immunology Reserch

Cancer Immunol Res. 2025 Jan 13. doi: 10.1158/2326-6066.CIR-24-1003. Online ahead of print. ABSTRACT Tumor-specific HLA class I expression is required for cytotoxic T-cell elimination of cancer cells expressing tumor-associated or neo-antigens. Cancers downregulate antigen presentation to avoid adaptive immunity. The highly polymorphic nature of the genes encoding these proteins, coupled with quaternary-structure changes after formalin … Read more

Cancer Immunol Res. 2025 Jan 9. doi: 10.1158/2326-6066.CIR-24-0857. Online ahead of print. ABSTRACT T cell-based therapies, including Tumor Infiltrating Lymphocyte Therapy (TIL), T cell receptor engineered T cells (TCR T), and Chimeric Antigen Receptor T cells (CAR T), are powerful therapeutic approaches for cancer treatment. While these therapies are primarily known for their direct cytotoxic … Read more

Cancer Immunol Res. 2025 Jan 9. doi: 10.1158/2326-6066.CIR-23-0563. Online ahead of print. ABSTRACT The immune composition of solid tumors is typically inferred from biomarkers, such as histologic and molecular classifications, somatic mutational burden, and PD-L1 expression. However, the extent to which these biomarkers predict the immune landscape in gastric adenocarcinoma-an aggressive cancer often linked to … Read more

Cancer Immunol Res. 2025 Jan 9:OF1-OF19. doi: 10.1158/2326-6066.CIR-23-1011. Online ahead of print. ABSTRACT Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute to resistance to CAR T-cell therapy in solid tumors, and appropriate model … Read more

Cancer Immunol Res. 2025 Jan 9;13(1):7. doi: 10.1158/2326-6066.CIR-13-1-WWR. NO ABSTRACT PMID:39780660 | DOI:10.1158/2326-6066.CIR-13-1-WWR

Cancer Immunol Res. 2025 Jan 7. doi: 10.1158/2326-6066.CIR-24-0775. Online ahead of print. ABSTRACT Interleukin-12 (IL-12) is a potent NK cell-stimulating cytokine, but the presence of immunosuppressive myeloid cells such as myeloid-derived suppressor cells (MDSC) can inhibit IL 12-induced NK-cell cytotoxicity. Thus, we hypothesized that trabectedin, a myeloid cell-depleting agent, would improve the efficacy of IL-12 … Read more

Cancer Immunol Res. 2025 Jan 7. doi: 10.1158/2326-6066.CIR-24-0445. Online ahead of print. ABSTRACT Anaplastic lymphoma kinase (ALK)-fusion proteins resulting from chromosomal rearrangements are promising targets for cancer immunotherapy. While ALK-specific CD8+ T cells and epitopes presented on MHC class I have been identified in patients with ALK-positive malignancies, little is known about ALK-specific CD4+ T … Read more

Cancer Immunol Res. 2025 Jan 7. doi: 10.1158/2326-6066.CIR-24-0421. Online ahead of print. ABSTRACT Dendritic cells (DCs) are promising targets for cancer immunotherapies because of their central role in the initiation and control of immune responses. The rare cDC1 population is of particular interest because of its remarkable ability to cross-present antigens (Ag) to CD8+ T … Read more

Cancer Immunol Res. 2025 Jan 6:OF1-OF19. doi: 10.1158/2326-6066.CIR-24-0298. Online ahead of print. ABSTRACT Despite advances in cancer immunotherapy, such as targeting the PD-1/PD-L1 axis, a substantial number of patients harbor tumors that are resistant or relapse. Selective engagement of T-cell co-stimulatory molecules with bispecific antibodies may offer novel therapeutic options by enhancing signal 1-driven activation … Read more

Cancer Immunol Res. 2025 Jan 2. doi: 10.1158/2326-6066.CIR-24-0589. Online ahead of print. ABSTRACT Despite the pivotal role of cytotoxic T lymphocytes (CTLs) in anti-tumor immunity, a substantial proportion of CTL-rich hepatocellular carcinoma (HCC) patients experience early relapse or immunotherapy resistance. However, spatial immune variations impacting the heterogeneous clinical outcomes of CTL-rich HCCs remain poorly understood. … Read more